GIP Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: native GIP human physiology

Metabolic Research peptide Lyophilized verified

Also known as: Glucose-dependent insulinotropic polypeptide

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

1 mg, 5 mg

Calculator

Preset available

Storage

Lyophilized: store at -20 deg C. After reconstitution: refrigerate 2-8 deg C; verify beyond-use timing against source COA.

Solubility

Research formulation dependent

Catalog Description

GIP (Glucose-dependent Insulinotropic Polypeptide) is an incretin hormone secreted by intestinal K-cells in response to nutrient intake, stimulating glucose-dependent insulin secretion. Co-agonism of GLP-1R and GIPR (as in tirzepatide) is associated with greater metabolic effects than GLP-1R agonism alone in clinical trials; GIPR is also expressed in adipose tissue, bone, and brain, suggesting broader physiological roles still being characterized. Standalone GIP-receptor-targeted therapeutics are an active research area but less independently mature than the GLP-1 monotherapy literature.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Native GIP is rapidly inactivated by DPP-4 with an active circulating half-life of approximately 7 minutes

Onset

Hormonal effects occur during acute infusion

Administration Routes (Research)

IV in human physiology studiesLaboratory use

Reported Research Effects

Glucose-dependent insulin secretion (incretin effect)
Co-agonism with GLP-1R (tirzepatide) shows greater metabolic effect than GLP-1R alone
Expressed in adipose tissue, bone, and brain - broader roles under investigation

Reported Research Side Effects

Glucose-dependent insulin stimulation
Glucagon stimulation during fasting or hypoglycemia
Heart-rate and appetite effects reported in infusion studies

Data source: Primary human incretin physiology studies

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

1.5-4 pmol/kg/min as a physiology-study infusion [IV; 60 minutes to 4 hours; Continuous]Source: human clamp and appetite studies

Research Interactions

Flagged Avoid / Caution Combinations (Research)

Do not substitute tirzepatide dosing; tirzepatide is a distinct engineered dual agonist

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

The previous row improperly imported tirzepatide's weekly dose into a native GIP entry. Native GIP and tirzepatide differ in sequence, receptor profile, stability, and pharmacokinetics.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Glucose-dependent insulin and glucagon effects of GIP — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/21984584/

GIP and GLP-1 appetite infusion study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/30683945/

GIP physiology infusion study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/19178509/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.